AU598268B2 - A process for the preparation of a pasteurized immunoglobulin preparation - Google Patents
A process for the preparation of a pasteurized immunoglobulin preparation Download PDFInfo
- Publication number
- AU598268B2 AU598268B2 AU74087/87A AU7408787A AU598268B2 AU 598268 B2 AU598268 B2 AU 598268B2 AU 74087/87 A AU74087/87 A AU 74087/87A AU 7408787 A AU7408787 A AU 7408787A AU 598268 B2 AU598268 B2 AU 598268B2
- Authority
- AU
- Australia
- Prior art keywords
- immunoglobulin
- solution
- acid
- preparation
- carboxylic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 49
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241000700605 Viruses Species 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 8
- 244000052769 pathogen Species 0.000 claims abstract description 5
- 208000006454 hepatitis Diseases 0.000 claims abstract description 3
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 3
- 238000011321 prophylaxis Methods 0.000 claims abstract 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 26
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 229930006000 Sucrose Natural products 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- 239000004471 Glycine Substances 0.000 claims description 13
- 229920000642 polymer Polymers 0.000 claims description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 150000001735 carboxylic acids Chemical group 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 1
- 210000002837 heart atrium Anatomy 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 229960004793 sucrose Drugs 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 229940072221 immunoglobulins Drugs 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 5
- 229940049906 glutamate Drugs 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000013923 monosodium glutamate Nutrition 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 229940073490 sodium glutamate Drugs 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- -1 alkaline earth metal salt Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000003918 fraction a Anatomy 0.000 description 2
- 230000001175 peptic effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010032597 Cohn fraction II Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000408495 Iton Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003171 anti-complementary effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- VPEKJHZFKNQFES-BHRFRFAJSA-N diazanium (2S)-2,6-diaminohexanoic acid sulfate Chemical compound N[C@@H](CCCCN)C(=O)O.S(=O)(=O)([O-])[O-].[NH4+].[NH4+] VPEKJHZFKNQFES-BHRFRFAJSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863619565 DE3619565A1 (de) | 1986-06-11 | 1986-06-11 | Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation |
| DE3619565 | 1986-06-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7408787A AU7408787A (en) | 1987-12-17 |
| AU598268B2 true AU598268B2 (en) | 1990-06-21 |
Family
ID=6302735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU74087/87A Ceased AU598268B2 (en) | 1986-06-11 | 1987-06-10 | A process for the preparation of a pasteurized immunoglobulin preparation |
Country Status (10)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4762714A (en) * | 1986-04-08 | 1988-08-09 | Miles Laboratories, Inc. | Preparation of retrovirus-free immunoglobulins |
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| DE4344824C1 (de) * | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| EP2850099B1 (en) * | 2012-05-14 | 2017-01-18 | Novo Nordisk A/S | Stabilised protein solutions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3239184A (en) * | 1983-08-26 | 1985-02-28 | Aventis Behring Gmbh | Process for the pasteurization of human plasma |
| AU1664288A (en) * | 1987-05-22 | 1988-11-24 | Armour Pharmaceutical Products, Inc. | Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5840532B2 (ja) * | 1975-04-08 | 1983-09-06 | カブシキガイシヤ ミドリジユウジ | Ｉｇａ オヨビ ｉｇｍ ノネツアンテイカホウ |
| DE3176491D1 (en) * | 1980-03-05 | 1987-11-26 | Miles Lab | Pasteurized therapeutically active protein compositions |
| JPS57140724A (en) * | 1981-02-25 | 1982-08-31 | Green Cross Corp:The | Heat-treatment of aqueous solution containing cold insoluble globulin |
| DE3473407D1 (en) * | 1983-05-02 | 1988-09-22 | Immuno Ag | Method of inactivating pathogens |
| JPH0669961B2 (ja) * | 1984-09-25 | 1994-09-07 | 株式会社ミドリ十字 | 免疫グロブリンの加熱処理方法 |
| JPH0825902B2 (ja) * | 1985-02-21 | 1996-03-13 | 株式会社ミドリ十字 | γ−グロブリンの加熱処理方法 |
| JPH0825903B2 (ja) * | 1985-05-16 | 1996-03-13 | 株式会社ミドリ十字 | γ―グロブリン含有水溶液 |
-
1986
- 1986-06-11 DE DE19863619565 patent/DE3619565A1/de not_active Withdrawn
-
1987
- 1987-06-05 ES ES87108170T patent/ES2059323T3/es not_active Expired - Lifetime
- 1987-06-05 AT AT87108170T patent/ATE95067T1/de not_active IP Right Cessation
- 1987-06-05 DE DE87108170T patent/DE3787569D1/de not_active Revoked
- 1987-06-05 EP EP87108170A patent/EP0249167B1/de not_active Revoked
- 1987-06-09 FI FI872578A patent/FI92557C/fi not_active IP Right Cessation
- 1987-06-09 PT PT85052A patent/PT85052B/pt active IP Right Revival
- 1987-06-10 CA CA000539495A patent/CA1340737C/en not_active Expired - Lifetime
- 1987-06-10 DK DK296387A patent/DK296387A/da not_active Application Discontinuation
- 1987-06-10 AU AU74087/87A patent/AU598268B2/en not_active Ceased
- 1987-06-10 JP JP62143449A patent/JPS62292731A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3239184A (en) * | 1983-08-26 | 1985-02-28 | Aventis Behring Gmbh | Process for the pasteurization of human plasma |
| AU1664288A (en) * | 1987-05-22 | 1988-11-24 | Armour Pharmaceutical Products, Inc. | Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants |
Also Published As
| Publication number | Publication date |
|---|---|
| PT85052B (pt) | 1990-03-08 |
| DE3787569D1 (de) | 1993-11-04 |
| JPS62292731A (ja) | 1987-12-19 |
| ES2059323T3 (es) | 1994-11-16 |
| EP0249167A2 (de) | 1987-12-16 |
| FI92557C (fi) | 1997-12-02 |
| DE3619565A1 (de) | 1987-12-17 |
| CA1340737C (en) | 1999-09-14 |
| FI872578A0 (fi) | 1987-06-09 |
| FI872578L (fi) | 1987-12-12 |
| PT85052A (de) | 1987-07-01 |
| FI92557B (fi) | 1994-08-31 |
| ATE95067T1 (de) | 1993-10-15 |
| EP0249167B1 (de) | 1993-09-29 |
| AU7408787A (en) | 1987-12-17 |
| EP0249167A3 (en) | 1989-05-10 |
| DK296387D0 (da) | 1987-06-10 |
| DK296387A (da) | 1987-12-12 |
| JPH0525862B2 (enrdf_load_stackoverflow) | 1993-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2155630C (en) | Low temperature albumin fractionation using sodium caprylate as a partitioning agent | |
| EP2270044B1 (en) | Liquid immunoglobulin G (lgG) product | |
| US6281336B1 (en) | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products | |
| KR0152256B1 (ko) | 면역글로불린을 함유하는 정맥내투여용 폴리클로날 면역글로불린 제제 및 이의 제조방법 | |
| EP0058993B1 (en) | Process for heat treatment of aqueous solution containing cold insoluble globulin | |
| US4876088A (en) | Gamma-globulin injectable solutions containing sorbitol | |
| US4251510A (en) | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production | |
| SK287633B6 (sk) | Spôsob výroby humánneho gamaglobulínu G a humánny gamaglobulín G s inaktivovanými vírusmi | |
| EP0967995A1 (en) | Composition comprising immunoglobulin | |
| US4378346A (en) | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production | |
| US4164495A (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| US5075425A (en) | Process for the preparation of a pharmaceutical which contains igg, iga and igm and can be administered intravenously | |
| EP0764447B1 (en) | Preparation of virally inactivated intravenously injectable immune serum globulin | |
| AU598268B2 (en) | A process for the preparation of a pasteurized immunoglobulin preparation | |
| US5248767A (en) | Process for the preparation of a pasteurized immunoglobulin preparation using ethanol | |
| CA2150612A1 (en) | Process for producing albumin preparation | |
| EP0449897B1 (en) | A pure factor i protein and a process for producing said protein | |
| AU2016231646B2 (en) | Method for the preparation of immunoglobulins | |
| JPH0761935A (ja) | 静注用免疫グロブリン製剤の製造方法 | |
| CA2943328A1 (en) | Method for the preparation of immunoglobulins | |
| HK1151045B (en) | Liquid immunoglobulin g (lgg) product | |
| HK1151044B (en) | Process for manufacturing immunoglobulins for intravenous administration and other immunoglobulin-like products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: AVENTIS BEHRING GMBH Free format text: FORMER NAME WAS: CENTEON PHARMA GMBH |